As the Australian market navigates a period of fluctuating performance, with recent gains tempered by external pressures such as rising oil prices and missed opportunities in the AI sector, investors are on the lookout for stocks that may be trading below their estimated value. In this environment, identifying undervalued stocks requires careful analysis of fundamentals and market conditions, making Integral Diagnostics and two other ASX-listed companies worthy of consideration for those seeking potential value investments. Top 10 Undervalued Stocks Based On Cash Flows In Australia Name Current Price Fair Value (Est) Discount (Est) Wrkr (ASX:WRK) A$0.11 A$0.21 46.7% Web Travel Group (ASX:WEB) A$2.44 A$4.77 48.8% Symal Group (ASX:SYL) A$2.58 A$4.79 46.1% ReadyTech Holdings (ASX:RDY) A$1.35 A$2.48 45.5% Nuix (ASX:NXL) A$1.43 A$2.56 44.2% Lovisa Holdings (ASX:LOV) A$22.21 A$41.97 47.1% Judo Capital Holdings (ASX:JDO) A$1.395 A$2.51 44.4% Integral Diagnostics (ASX:IDX) A$2.11 A$3.97 46.8% Capricorn Metals (ASX:CMM) A$13.56 A$26.17 48.2% Boss Energy (ASX:BOE) A$1.32 A$2.63 49.8% Click here to see the full list of 39 stocks from our Undervalued ASX Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Integral Diagnostics Overview: Integral Diagnostics Limited is a healthcare services company that offers diagnostic imaging services to medical professionals and their patients in Australia and New Zealand, with a market cap of A$785.95 million. Operations: The company's revenue is primarily derived from the operation of diagnostic imaging facilities, amounting to A$767.82 million. Estimated Discount To Fair Value: 46.8% Integral Diagnostics is trading at A$2.11, significantly below its estimated future cash flow value of A$3.97, indicating potential undervaluation based on discounted cash flows. Despite a dividend yield of 3.46% not being well covered by earnings or free cash flows, the company has shown strong earnings growth of 147.8% over the past year and forecasts suggest continued robust profit growth at 32.76% annually. However, interest payments are not well covered by earnings, which could pose financial challenges ahead amidst ongoing strategic expansion efforts including new site openings and M&A opportunities. The analysis detailed in our Integral Diagnostics growth report hints at robust future financial performance. Get an in-depth perspective on Integral Diagnostics' balance sheet by reading our health report here.ASX:IDX Discounted Cash Flow as at May 2026 Nuix Overview: Nuix Limited offers investigative analytics and intelligence software solutions across various regions including Asia Pacific, the Americas, Europe, the Middle East, and Africa, with a market cap of A$484.42 million. Story Continues Operations: The company's revenue primarily comes from its Software & Programming segment, which generated A$237.49 million. Estimated Discount To Fair Value: 44.2% Nuix is trading at A$1.43, below its estimated future cash flow value of A$2.56, highlighting potential undervaluation based on discounted cash flows. The company has transitioned to profitability with recent earnings of A$11.08 million for the half-year ending December 2025, reversing a prior net loss. Despite being dropped from key indices in March 2026, Nuix's earnings are forecast to grow significantly at 38.2% annually, although its return on equity remains modestly projected at 8.6%. Our comprehensive growth report raises the possibility that Nuix is poised for substantial financial growth. Take a closer look at Nuix's balance sheet health here in our report.ASX:NXL Discounted Cash Flow as at May 2026 WiseTech Global Overview: WiseTech Global Limited develops and provides software solutions for the logistics execution industry across various regions, with a market cap of A$12.67 billion. Operations: Revenue segments for WiseTech Global include software solutions for logistics execution across the Americas, Asia Pacific, Europe, the Middle East, and Africa. Estimated Discount To Fair Value: 17.2% WiseTech Global is trading at A$38.01, below its estimated future cash flow value of A$45.90, suggesting potential undervaluation. Despite a decline in profit margins to 15.2% from last year's 27.3%, earnings are expected to grow significantly at 30.2% per year, outpacing the Australian market's forecasted growth rate of 12%. However, revenue growth is slower than desired and debt coverage by operating cash flow remains inadequate, posing financial risks. Upon reviewing our latest growth report, WiseTech Global's projected financial performance appears quite optimistic. Click here to discover the nuances of WiseTech Global with our detailed financial health report.ASX:WTC Discounted Cash Flow as at May 2026 Taking Advantage Explore the 39 names from our Undervalued ASX Stocks Based On Cash Flows screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Ready For A Different Approach? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:IDX ASX:NXL and ASX:WTC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Integral Diagnostics And 2 Other ASX Stocks That May Be Trading Below Estimated Value
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...